CA-AUTOGRID
11.5.2022 14:02:11 CEST | Business Wire | Press release
AutoGrid, the leader in artificial intelligence (AI)-driven optimization for distributed energy resources (DERs), announced today that it has signed a definitive agreement to be acquired by Schneider Electric, the global specialist in energy management and automation. The transaction is subject to regulatory approval and other customary closing conditions and is expected to close in Q3, 2022. The acquisition will provide AutoGrid with the resources and global reach to accelerate its growth and pace of product innovation.
“Schneider Electric and AutoGrid have a shared vision for a more sustainable world through electrification, digitization and decarbonization. With AutoGrid, we can deliver significant value to energy companies by delivering cutting-edge technologies to drive adoption of smart grids and reduction of carbon emissions,” said Nadège Petit, Chief Innovation Officer at Schneider Electric. “We are excited to create maximum impact with our customers by accelerating the reach and scale of AutoGrid.”
Schneider Electric and AutoGrid have been working together as partners since 2015 and announced a fully integrated Advanced Distribution Management System (ADMS) and Distributed Energy Resources Management System (DERMS) two years ago. In January 2022, the energy industry’s leading independent research firm Guidehouse Research ranked the Schneider Electric - AutoGrid DERMS solution as #1 in the world.
“Joining forces with AutoGrid will give customers the most advanced platform to integrate and orchestrate distributed energy resources for the benefit of all grid stakeholders,” said Luis D’Acosta, Executive Vice President of Digital Energy at Schneider Electric. “These new capabilities will accelerate prosumer engagement for a more sustainable and efficient grid.”
AutoGrid’s technology plays a direct role in combating climate change. For over a decade, AutoGrid has pioneered the science of flexibility management to enable wide-scale renewable energy adoption. Their democratized energy internet smooths out sudden fluctuations in renewable energy supply and customer energy demands. AutoGrid’s AI-powered Virtual Power Plant (VPP) and Distributed Energy Resources Management (DERMS) Platform offers a sustainable alternative to dirty and expensive fossil-fuel dependent backup power plants by managing and deploying additional untapped capacity from batteries, electric vehicles and flexible load. AutoGrid has transformed the century-old, one-way, electricity grid architecture into a two-way flow of electrons that gives consumers the freedom and economic incentive to combat climate change with their energy decisions
“We started AutoGrid with the singular mission of accelerating the world's access to sustainable energy,” said Amit Narayan, Founder and CEO of AutoGrid. “I am grateful for the help we have received from Schneider Electric as an ardent supporter throughout this journey. I can say with confidence that we couldn’t have found a better partner who is more aligned in terms of our values and commitment to the mission to decarbonize our planet. I am now looking forward to the next chapter to scale our technology even faster to solve this urgent climate crisis facing us.”
About AutoGrid
Founded in 2010, with the mission of combatting climate change by accelerating access to clean, affordable & reliable energy globally. AutoGrid’s AI-driven software empowers energy consumers, creators and distributors with a smart orchestration platform giving them access to electric vehicles, batteries, roof-top solar, utility-scale wind and other distributed energy resources (DERs). By enabling prediction, optimization, and real-time control of millions of energy assets at an unprecedented scale, AutoGrid is making the vision of a decentralized, decarbonized, and democratized new energy world a reality.
With over a decade of pioneering innovation across the globe, AutoGrid offers fleet owners, energy-as-a-service companies, renewable project developers, utilities, and electricity retailers the ability to build, own, operate, and participate in intelligent and scalable Virtual Power Plants (VPPs) enabling them to break their dependency on fossil-fuel based energy. AutoGrid Flex platform is managing over 6,000 MW of VPPs in 15 countries – everything from an electric vehicles, storage or solar panels in a home, to microgrids in a campus or industrial site, and utility scale storage and renewable farms – and is ranked as the #1 Virtual Power Plant and the #1 Distributed Energy Resources Management Platform in the world (according to the latest global ranking by industry-leading research and analysis firm Guidehouse Insights).
Additional info can be found at: http://www.auto-grid.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005251/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom